logo-loader
viewMaxCyte Inc

Healthcheck on cell therapy group MaxCyte

MaxCyte Inc (LON:MXCT) updates investors on its cellular editing technology ahead of new results out tomorrow.
CEO Doug Doefler tells Proactive London why short/medium and long term goals for the company are bang on track as he looks forward to a  new generation of cell therapy techniques that MaxCyte intends to develop.
The company provides patented, high-performance cell-engineering platforms to bio-pharmaceutical partners engaged in drug discovery and development, bio-manufacturing and cell therapy, including gene editing and immuno-oncology.

Quick facts: MaxCyte Inc

Price: 200 GBX

AIM:MXCT
Market: AIM
Market Cap: £153.17 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of MaxCyte Inc named herein, including the promotion by the Company of MaxCyte Inc in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

MaxCyte deal with Caribou 'demonstrates expertise and value' of its Flow...

Proactive Research analyst Emma Ulker discusses MaxCyte’s (LON:MXCT) new clinical and commercial licence agreement with Caribou Biosciences. She says the agreement which allows the use of its proprietary Flow Electroporation technology for Caribou’s CRISPR gene-edited allogeneic T-cell...

on 11/5/20

2 min read